文献速递肾癌与肾肿瘤

超越透明细胞癌:重新审视非透明细胞肾细胞癌亚型术后监测

Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes.
PubMed 文献 · Eur Urol Oncol · 2026-04-29

本研究回顾性分析2003-2015年接受手术的非转移性非透明细胞肾细胞癌(nccRCC)患者,评估术后复发模式并比较AUA、EAU与NCCN指南的风险分层效能。队列以乳头状RCC为主(420/712,59%),腹部是最常见复发部位,晚期复发(>5年)占全部复发的27%,现行指南在nccRCC中的适用性受到挑战。

要点

  • nccRCC术后复发以腹部最常见(44/116,38%),支持继续腹部横断面影像监测
  • 晚期复发(>5年)占全部复发的27%,不应在5年时停止监测
  • AUA风险分层区分度优于EAU和NCCN(C-index 0.69 vs 0.67 vs 0.66)

核心结论

  • 本以乳头状RCC和嫌色细胞RCC为主的nccRCC队列结果挑战现行nccRCC监测指南:腹部复发最常见,支持继续横断面影像监测。
  • 晚期复发(>5年)常见,反对在5年时终止监测,提示需改进风险适应性监测方案。

研究设计与样本

  • 单中心回顾性研究,分析2003-2015年接受手术的非转移性nccRCC患者。
  • 按AUA、EAU和NCCN风险分组进行分层,采用C-index、IBS和校准曲线评估模型效能。
  • 以捕获95%复发所需时间及10年条件复发风险降至5%以下所需时间定义最佳监测时长,并将非RCC死亡作为竞争风险。

主要发现

  • 乳头状RCC为最常见亚型(420/712,59%),中位随访11.6年(IQR:133-148月)。
  • 116例患者出现复发,最常见部位为腹部(44/116,38%);5年无复发生存率为86%(95%CI:83-89)。
  • 嫌色细胞RCC的期别校正复发亚分布风险比最低(sHR:0.21,95%CI:0.12-0.40)。
  • AUA风险分层的区分度更高、预测误差更低(C-index 0.69,IBS 0.104),优于EAU(C-index 0.67,IBS 0.118)和NCCN(C-index 0.66,IBS 0.115)。
  • 晚期复发(>5年)占全部观察到的复发的27%。

关键数值与推荐

  • 5年无复发生存率为86%(95%CI:83-89)。
  • 嫌色细胞RCC期别校正复发sHR为0.21(95%CI:0.12-0.40)。
  • AUA、EAU、NCCN的C-index分别为0.69、0.67、0.66,IBS分别为0.104、0.118、0.115。

临床怎么用

  • nccRCC术后应继续腹部横断面影像监测,因腹部是最常见复发部位。
  • 不应在术后5年停止监测,需关注5年以上的晚期复发。
  • 可优先参考AUA风险分层进行风险适应性监测安排。

局限性

  • 单中心回顾性研究,结果可能不具广泛普适性。
  • 监测时长相关指标应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Current risk stratification for non-clear cell renal cell carcinoma (nccRCC) is largely derived from clear cell RCC (ccRCC) data. We evaluated recurrence patterns following surgery for nccRCC and compared the prognostic performances of various international guidelines. METHODS: We retrospectively analyzed patients with surgically managed nonmetastatic nccRCC (2003-2015). Patients were stratified by American Urological Association (AUA), European Association of Urology (EAU), and National Comprehensive Cancer Network (NCCN) risk groups. Model performance was assessed via C-index, integrated Brier score (IBS), and calibration plots. Optimal surveillance duration was defined as the time required to capture 95% of recurrences and the time until the 10-yr conditional recurrence risk fell below 5%, accounting for non-RCC deaths as a competing risk. KEY FINDINGS AND LIMITATIONS: Papillary RCC (pRCC) was the most common subtype (420/712, 59%). Median follow-up was 11.6 yr (IQR: 133-148 mo). Recurrences occurred in 116 patients, most frequently in the abdomen (44/116, 38%). The 5-yr recurrence-free survival (RFS) was 86% (95% confidence interval [CI]: 83-89). Chromophobe RCC (chRCC) had the lowest stage-adjusted subdistribution hazard of recurrence (sHR) (sHR: 0.21, 95% CI: 0.12-0.40). AUA risk-stratification schema provided higher discrimination and lower prediction error (C-index 0.69, IBS 0.104) compared with that of EAU (C-index 0.67, IBS 0.118) and NCCN (C-index 0.66, IBS 0.115). Late recurrences (>5 yr) were common, comprising 27% of all observed recurrences. As a single-center, retrospective study, these findings may not be broadly generalizable. Surveillance duration metrics should be interpreted with caution. CONCLUSIONS AND CLINICAL IMPLICATIONS: Outcomes in this predominantly pRCC and chRCC cohort challenge the current nccRCC surveillance guidelines: abdominal recurrences were the most common, supporting continued cross-sectional imaging. Late recurrences (>5 yr) argue against stopping surveillance at 5 yr and highlight the need for improved risk-adapted surveillance schedules. PATIENT SUMMARY: Current national guidelines for postsurgery follow-up for kidney cancer are based on its most common type. However, their appropriateness for less common forms remains unknown. This study shows that the less common form, non-clear cell renal cell carcinoma, primarily comes back after surgery in the abdomen and can often come back more than 5 yr postoperatively. Therefore, doctors should monitor these patients for a longer duration and focus on abdominal imaging to enable earlier detection. Advancing practice.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Das A, Ellis EE, Tamboli P, et al. Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes. Eur Urol Oncol. 2026. PMID: 42055880. doi:10.1016/j.euo.2026.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。